Syros to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 2, 2023

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) will host a live conference call and webcast on March 2, 2023, at 8:30 a.m. ET to discuss its fourth quarter and full year 2022 financial results. The call can be accessed by dialing (888) 575-5167 for domestic callers or (416) 764-8687 for international callers, using conference ID 74534085. Syros focuses on advancing treatment standards for hematologic malignancies. Its clinical pipeline includes tamibarotene for higher-risk myelodysplastic syndrome and acute myeloid leukemia, and SY-2101, an oral arsenic trioxide formulation for acute promyelocytic leukemia. More details are available on their website.

Positive

• Syros is advancing a robust late-stage clinical pipeline.
• Tamibarotene targets higher-risk myelodysplastic syndrome and acute myeloid leukemia.

Negative

• None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, March 2, 2023 to report its fourth quarter and full year 2022 financial results and provide a corporate update.

To access the live conference call, please dial (888) 575-5167 (domestic) or (416) 764-8687 (international) and refer to conference ID 74534085. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the call.

About Syros Pharmaceuticals

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is advancing a robust late-stage clinical pipeline, including tamibarotene, a first-in-class oral selective RARα agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is also seeking partnerships for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and multiple preclinical programs in oncology and monogenic diseases. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005030/en/

Syros Contact

Karen Hunady

Director of Corporate Communications & Investor Relations

1-857-327-7321

khunady@syros.com

Media Contact

Brittany Leigh, Ph.D.

LifeSci Communications, LLC

+1-813-767-7801

bleigh@lifescicomms.com

Investor Contact

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Source: Syros Pharmaceuticals

FAQ

When will Syros Pharmaceuticals report its Q4 2022 financial results?

Syros Pharmaceuticals will report its fourth quarter and full year 2022 financial results on March 2, 2023.

What is the purpose of the conference call on March 2, 2023 by Syros Pharmaceuticals?

The conference call will discuss Syros Pharmaceuticals' fourth quarter and full year 2022 financial results and provide a corporate update.

How can I access the Syros Pharmaceuticals conference call on March 2, 2023?

You can access the conference call by dialing (888) 575-5167 for domestic or (416) 764-8687 for international callers, using conference ID 74534085.